Efficacy of Noisome as A Carrier of Locally Delivered Minocycline Hydrochloride Gel

Periodontitis Clinical Trial

Official title:

"Efficacy of Noisome as A Carrier of Locally Delivered Minocycline Hydrochloride Gel in Stage II or Stage III Periodontitis: A Randomized Controlled Clinical Trial With Biochemical Analysis"

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06255067
• Other study ID #: FDASU-RecIM022002
• Status: Not yet recruiting
• Phase: Phase 2/Phase 3
• Start date: February 25, 2024
• Est. completion date: June 30, 2024

Study information

• Verified date: February 2024
• Source: Ain Shams University
• Contact: Israa Said, B.D.S
• Phone: +201096872828
• Email: israasaiid94[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare the efficacy of Noisome as carrier of minocycline hydrochloride gel to minocycline hydrochloride in Stage II or Stage III Periodontitis . The main questions it aims to answer are:

• Is the Noisome carrier of minocycline hydrochloride has an effect in comparing to minocycline hydrochloride in Stage II or Stage III Periodontitis?

• what is the release profile of of minocycline hydrochloride noisome gel and minocycline hydrochloride gel? Participants will be asked to maintain oral hygiene after application of treatment Researchers will compare the effect of noisome as a carrier of locally delivered minocycline hydrochloride gel to minocycline hydrochloride gel in stage II or stage III periodontitis patients as an adjunct to non-surgical periodontal treatment] to see if Plaque Index (PI) , Gingival index,Clinical attachment level (CAL) &Periodontal Pocket Depth decreased or not.

Description:

This study is designed to be a Randomized, Controlled, blinded, clinical trial; the eligible participants will be randomly allocated for one of the two comparative parallel-Groups; test and control group . The interventions will be prepared by the pharmacist and coded and the whole-time frame for the study will be 18 weeks.

The intervention to all participants will be Non-surgical debridement the the test group will receive the Noisome minocycline hydrochloride & control group will receive minocycline hydrochloride.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: June 30, 2024
• Est. primary completion date: May 25, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 50 Years

Eligibility

Inclusion Criteria:

• Participants willing to commit for the entire period of the trial and agreed to sign the written consent after full explanation of the study.

• Generalized Periodontitis (Stage II or stage III ) Patients; ( = 3 mm CAL, PD 5-7 mm ) , premolar-molar area (test site) .

• Having more than 16 tooth excluding wisdom and test teeth that still had both mesial and distal neighboring teeth.

• Systemically free according to the modified Burkitt's health history questionnaire

Exclusion Criteria:

• Non-surgical periodontal therapy within the previous 12 months, systemic or local use of antibiotics with the previous 3 months, medication with possible influence on the periodontium.

• Pregnancy or contraceptives usage.

• Breastfeeding.

• Known allergy to the ingredients of the treatment.

• Smokers.

• vulnerable group; prisoners & orphans .

Related Conditions & MeSH terms

• Periodontitis

Intervention

Drug:
• Minocycline hydrochloride with noisome carrier
patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days
• Minocycline Hydrochloride only
patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days

Locations

Country	Name	City	State
Egypt	AinShams University	Cairo
Egypt	AinShams University	Cairo

Sponsors (2)

Lead Sponsor	Collaborator
Ain Shams University	faculty of pharmacy Tanta University

Country where clinical trial is conducted

Egypt, 

References & Publications (6)

Apatzidou DA, Kinane DF. Nonsurgical mechanical treatment strategies for periodontal disease. Dent Clin North Am. 2010 Jan;54(1):1-12. doi: 10.1016/j.cden.2009.08.006. — View Citation

Cortelli JR, Querido SM, Aquino DR, Ricardo LH, Pallos D. Longitudinal clinical evaluation of adjunct minocycline in the treatment of chronic periodontitis. J Periodontol. 2006 Feb;77(2):161-6. doi: 10.1902/jop.2006.040409. — View Citation

Jain R, Mohamed F, Hemalatha M. Minocycline containing local drug delivery system in the management of chronic periodontitis: A randomized controlled trial. J Indian Soc Periodontol. 2012 Apr;16(2):179-83. doi: 10.4103/0972-124X.99259. — View Citation

Nakao R, Takigawa S, Sugano N, Koshi R, Ito K, Watanabe H, Senpuku H. Impact of minocycline ointment for periodontal treatment of oral bacteria. Jpn J Infect Dis. 2011;64(2):156-60. — View Citation

Uchegbu IF, Vyas SP (2015). Non-Ionic surfactant based vesicles (noisome) in drug delivery. Int J Pharm. ;172:33-70.

Williams RC, Paquette DW, Offenbacher S, Adams DF, Armitage GC, Bray K, Caton J, Cochran DL, Drisko CH, Fiorellini JP, Giannobile WV, Grossi S, Guerrero DM, Johnson GK, Lamster IB, Magnusson I, Oringer RJ, Persson GR, Van Dyke TE, Wolff LF, Santucci EA, Rodda BE, Lessem J. Treatment of periodontitis by local administration of minocycline microspheres: a controlled trial. J Periodontol. 2001 Nov;72(11):1535-44. doi: 10.1902/jop.2001.72.11.1535. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To measure clinical assessment Plaque Index (PI) in both groups (mincycline hydrochloride with noisome as carrier & minocycline hydrochloride only)	To measure the clinical parameter Plaque Index (PI) on score from zero to three; 0 = No plaque in gingival area.; = A film of plaque adhering to the free gingival margin and adjacent area of tooth. The plaque may be recognized only by running a probe across the tooth surface.; = Moderate accumulation of soft deposit within the gingival pocket and on the gingival pocket and on the gingival margin and/or adjacent tooth surface that can be seen by naked eye.; = Abundance of soft matter within the gingival pocket and/or on the gingival margin and adjacent tooth surface.	measured at the baseline, before the application of drug& after 18 weeks
Primary	To measure clinical assessment Gingival Index (GI) in both groups (mincycline hydrochloride with noisome as carrier & minocycline hydrochloride only)	To measure the clinical parameter gingival Index(GI) on score from zero to three; Gingival index (GI) 0 = Normal gingiva.; = Mild inflammation, slight change in color, slight edema; no bleeding on probing.; = Moderate inflammation, redness, edema, and glazing; bleeding on probing.; = Sever inflammation, marked redness and edema, ulceration; tendency to spontaneous bleeding.	measured at the baseline, before the application of drug& after 18 weeks
Primary	To measure Clinical attachment level (CAL) in both groups (mincycline hydrochloride with noisome as carrier & minocycline hydrochloride only)	To measure Clinical attachment level (CAL) in millimeter (mm).	measured at the baseline, before the application of drug& after 18 weeks
Primary	To measure Periodontal Pocket Depth (PPD) in both groups (mincycline hydrochloride with noisome as carrier & minocycline hydrochloride only)	To measure Periodontal Pocket Depth (PPD) in millimeter (mm).	measured at the baseline, before the application of drug& after 18 weeks
Secondary	- Evaluate the releasing profile of minocycline hydrochloride noisome gel and minocycline hydrochloride gel	change in number of releasing profile of each drug	first day then third day then seventh day lastly after fourteen days